Semler Scientific (SMLR)
(Delayed Data from NSDQ)
$33.52 USD
-0.10 (-0.30%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $33.42 -0.10 (-0.30%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$33.52 USD
-0.10 (-0.30%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $33.42 -0.10 (-0.30%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Omnicell (OMCL) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Omnicell's (OMCL) raises adjusted EPS guidance for 2021 , which buoys optimism.
Teleflex (TFX) Beats on Q1 Earnings and Revenues, Raises View
by Zacks Equity Research
The acquisition of Z-Medica and an increase in sales of new products contribute to Teleflex's (TFX) revenue growth in Americas in Q1
LabCorp (LH) Q1 Earnings Surpass Estimates, View Raised
by Zacks Equity Research
LabCorp's (LH) raises 2021 guidance but projects significant sinking of COVID-related testing revenues.
Amedisys (AMED) Q1 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Amedisys' (AMED) first-quarter 2021 revenues improves year over year on solid growth in the Home Health and Hospice divisions.
Integra (IART) Q1 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.
Chemed (CHE) Q1 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Chemed's (CHE) first-quarter 2021 revenues increase year-over-year on solid growth across its Roto-Rooter arm.
Boston Scientific (BSX) Q1 Earnings Beat, Organic Sales Up
by Zacks Equity Research
Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.
Semler Scientific Inc. (SMLR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Semler Scientific Inc. (SMLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Q1 Earnings Miss, Base Recovery Strong
by Zacks Equity Research
The updated first-half 2021 outlook by Quest Diagnostics (DGX) looks impressive given its raised revenue and operating cash flow expectations.
HOLX vs. SMLR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HOLX vs. SMLR: Which Stock Is the Better Value Option?
3 Reasons Why Semler Scientific Inc. (SMLR) Is a Great Growth Stock
by Zacks Equity Research
Semler Scientific Inc. (SMLR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific
Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy
by Urmimala Biswas
MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.
HOLX vs. SMLR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HOLX vs. SMLR: Which Stock Is the Better Value Option?
Here is Why Growth Investors Should Buy Semler Scientific Inc. (SMLR) Now
by Zacks Equity Research
Semler Scientific Inc. (SMLR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HOLX or SMLR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. SMLR: Which Stock Is the Better Value Option?
Semler Scientific Inc. (SMLR) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 46.67% and 5.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
HOLX vs. SMLR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HOLX vs. SMLR: Which Stock Is the Better Value Option?
HOLX or SMLR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. SMLR: Which Stock Is the Better Value Option?
Top Ranked Momentum Stocks to Buy for November 17th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 17th
Top Ranked Momentum Stocks to Buy for November 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 12th
Semler Scientific Inc. (SMLR) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 258.82% and 24.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Semler Scientific Inc. (SMLR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Semler Scientific Inc. (SMLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FMS vs. SMLR: Which Stock Is the Better Value Option?
by Zacks Equity Research
FMS vs. SMLR: Which Stock Is the Better Value Option?
FMS or SMLR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
FMS vs. SMLR: Which Stock Is the Better Value Option?